Honigman Represents MetaVia Inc. in Closing of $9.3 Million Underwritten Public Offering: Law Firm, Attorneys, Lawyers

Recently, Honigman advised MetaVia Inc. (NASDAQ: MTVA), a clinical-stage biotechnology company primarily focused on creating new drugs to treat cardiometabolic diseases, on its underwritten public offering for gross proceeds of about $9.3 million, which includes the full exercise of the underwriter’s over-allotment to buy additional shares and warrants.